Zusammenfassung
Neuroendokrine Neoplasien des Magens (g-NEN) gehören zu den häufigsten neuroendokrinen Neoplasien des Verdauungstrakts. Aufgrund des zunehmenden Fortschritts der bildgebenden Qualität in der Endoskopie werden g‑NEN darüber hinaus häufiger diagnostiziert als früher. Neben der prognostischen Klassifikation der Weltgesundheitsorganisation (WHO) bzw. der TNM-Klassifikation gibt es zusätzlich die Differenzierung in 3 biologisch relevante Subtypen: Der Typ 1 repräsentiert den häufigsten Subtyp (70–80 %) und ist pathophysiologisch mit einer chronisch-atrophischen Gastritis (autoimmun sowie durch Helicobacter pylori bedingt) assoziiert. Die g‑NEN Typ 2 (5 %) treten im Rahmen der multiplen endokrinen Neoplasien Typ 1 bzw. des Zollinger-Ellison-Syndroms (MEN1/ZES) auf. Der Typ 3 (10–15 %) tritt isoliert auf und weist keine pathophysiologische Assoziation auf. Bei den Typen 1 und 2 liegt eine Hypergastrinämie vor. Sie sind gewöhnlich von geringer Größe, multipel auftretend und mit guter Prognose vergesellschaftet. Dagegen liegt beim Typ 3 in der Regel keine vermehrte Gastrinsekretion vor. Stattdessen handelt es sich um große, singulär auftretende, bösartige Tumoren (G3). Entsprechend des biologischen Verhaltens (Typ 1–3) unterscheidet sich die Therapie von der endoskopischen Abtragung und Surveillance bis hin zur chirurgischen Resektion mit Chemotherapie. Eine frühe g‑NEN-Typ-1-Diagnose geht bei entsprechender endoskopischer Therapie bzw. Surveillance in der Regel mit einer ausgezeichneten Prognose einher.
Abstract
Gastric neuroendocrine neoplasms (g-NEN) are one of the most frequent neuroendocrine neoplasia of the digestive system. Due to technical progress of endoscopy with high-definition imaging modalities, NEN are also diagnosed more frequently than in former times. Besides the prognostic World Health Organization (WHO) or TNM classification system, there is also the differentiation into three biological subgroups: type 1 represents the most frequent subtype (70–80%) and is associated with chronic atrophic gastritis (autoimmune or Helicobacter pylori mediated). Type 2 (5% of the cases) is associated with multiple endocrine neoplasia type 1 and Zollinger–Ellison syndrome (MEN1/ZES). Type 3 (10–15%) usually shows no association. Type 1 and 2 are related to hypergastrinemia. They are small in size, occur at multiple locations within the stomach and are of benign behavior. In contrast, type 3 is not related to an increased gastrin secretion, and this subtype is usually represented by a single, large gastric tumor that is of malignant nature. According to their biological behavior (type 1–3), the respective treatment varies from endoscopic resection to surgery with chemotherapy. Early detection of type 1 NEN with adequate endoscopic treatment and surveillance is associated with a very good prognosis.
Literatur
Modlin IM et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72
Yao JC et al (2008) One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
Ellis L, Shale MJ, Coleman MP (2010) Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 105:2563–2569
Scherübl H et al (2013) Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 19:9012–9019
Hauso O et al (2008) Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113:2655–2664
Scherübl H et al (2010) Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 42:664–671
Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G (2010) Neuroendocrine tumors of the small bowels are on the rise: early aspects and management. World J Gastrointest Endosc 2:325–334
Delle Fave G et al (2016) ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 103:119–124
Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E (1993) Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104:994–1006
Ruszniewski P et al (2006) Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 84:158–164
Knösel T, Reiter C, Schubert-Fritschle G, Altendorf-Hofmann A, Kirchner T (2017) Neuroendocrine neoplasia of the stomach: What is new? Pathologe 38:98–104
Modlin IM, Lye KD, Kidd M (2003) A 5‑decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959
Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89:471–476
Rindi G et al (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116:532–542
Borch K et al (2005) Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242:64–73
Rindi G et al (1996) Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20:168–172
Anlauf M et al (2007) Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch 451:29–38
Berna MJ et al (2008) A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 93:1582–1591
Klöppel G, Scherübl H (2010) Neuroendocrine tumors of the stomach. Risk stratification and therapy. Pathologe 31:182–187
Hou W, Schubert ML (2007) Treatment of gastric carcinoids. Curr Treat Options Gastroenterol 10:123–133
Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181
Rugge M, Genta RM, OLGA Group (2005) Staging gastritis: an international proposal. Gastroenterology 129:1807–1808
Rugge M et al (2007) Gastritis staging in clinical practice: the OLGA staging system. Gut 56:631–636
Dinis-Ribeiro M et al (2012) Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 44:74–94
Klöppel G et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90:162–166
Wiedenmann B et al (1994) Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy. Semin Oncol 21:29–32
Zimmer T et al (2000) Endoscopic ultrasonography of neuroendocrine tumours. Digestion 62(Suppl 1):45–50
Merola E et al (2012) Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 95:207–213
Uygun A et al (2014) Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol 109:71–74
Norton JA, Melcher ML, Gibril F, Jensen RT (2004) Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 136:1267–1274
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Azam-Zangeneh, M. Müller-Schilling und A. Kandulski geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
M. Ebert, Mannheim
M. Müller-Schilling, Regensburg
Rights and permissions
About this article
Cite this article
Azam-Zangeneh, H., Müller-Schilling, M. & Kandulski, A. Neuroendokrine Neoplasien des Magens. Gastroenterologe 13, 126–129 (2018). https://doi.org/10.1007/s11377-018-0231-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-018-0231-3
Schlüsselwörter
- Magentumoren
- Gastritis
- Multiple endokrine Neoplasie
- Karzinoid
- Gastrointestinale endoskopische Intervention